非血管支架市場（依產品類型、材料類型、應用和地區）2026 年至 2032 年

2026-2032年非血管支架市場評估

需要支架置入術的慢性疾病的盛行率正在上升，其中包括膽道疾病、胃腸道疾病和泌尿系統疾病。隨著人口老化，這些疾病的盛行率也在上升，推動了對非血管支架置入術等有效治療方案的需求。技術進步也在創新支架設計（例如生物分解性和藥物釋放型支架）的開發中發揮關鍵作用，改善了患者的治療效果，同時降低了血管再阻塞和移位等併發症的風險，從而推動市場成長，預計到2024年將超過12.1億美元，到2032年將達到17.1億美元。

此外，人們對微創手術的日益偏好也加速了非血管支架的應用，因為與傳統手術技術相比，非血管支架的恢復時間更短，風險更低。這些因素共同推動了非血管支架的需求，預計2026年至2032年期間，非血管支架市場將以約4.80%的複合年成長率進一步成長。

非血管支架市場定義/概述

非血管支架是用於打開或疏通膽管、輸尿管、食道和腸道等非血管器官管道或通道的醫療設備。其主要用於治療阻礙這些器官自然流動的阻塞、狹窄和腫瘤等疾病，為胃腸道、泌尿系統和呼吸系統疾病提供重要的解決方案。非血管支架的未來前景光明，因為生物分解性支架和藥物釋放型支架等支架材料和設計的進步有望改善患者預後、減少併發症並擴大其在更廣泛臨床應用中的使用。隨著慢性病盛行率的持續上升，對這些微創治療的需求也將成長，非血管支架將成為現代醫療保健中越來越重要的一部分。

慢性病的增加會推動非血管支架市場嗎？

慢性病盛行率的上升是非血管支架市場的主要驅動力。膽道、胃腸道和泌尿系統等慢性疾病通常需要置入術支架來保持管道和通道暢通。隨著這些疾病的日益普遍，尤其是在老年人群中，預計非血管支架的需求將會成長。例如，膽結石和腫瘤導致膽管阻塞等膽道疾病的發生率上升，需要使用膽道支架來緩解阻塞並改善患者預後。

2024年10月，波士頓科學公司宣布推出一種用於治療良性膽道狹窄的新型全覆膜金屬支架，這體現了公司持續致力於提高支架性能和患者安全性的創新。此類技術進步不僅將提高支架的有效性，還將擴大其在各種慢性疾病中的應用，從而推動市場成長。

2024年6月，美國食品藥物管理局（FDA）核准了一種新型藥物釋放型食道支架，為食道癌患者提供了新的治療選擇。此次核准標誌著監管機構對先進支架技術的支援日益增強，預計將推動該領域的進一步研發。隨著各國政府和醫療機構持續重視慢性病的治療，預計未來幾年非血管支架市場將穩定成長。

感染併發症風險的增加是否會阻礙非血管支架市場的發展？

併發症，尤其是感染疾病風險的增加，是阻礙非血管支架市場成長的主要隱患。支架相關感染疾病尤其令人擔憂，因為它可能對患者造成嚴重後果，包括延長住院時間、增加手術次數以及增加醫療費用。對此類併發症的擔憂可能會阻礙醫生和患者選擇支架治療，從而限制市場的潛在成長。

此外，感染風險可能會影響非血管支架的普及和使用。感染風險的增加可能會使醫護人員在推薦支架治療時保持謹慎，尤其是在脆弱的患者族群。儘管支架設計和材料方面已取得進展，以降低感染風險，但這種謹慎的態度可能會減緩新支架技術的普及。

除了這些直接影響外，感染疾病等併發症風險的增加可能導致新支架產品核准的監管要求更加嚴格，從而增加新支架上市的時間和成本，並阻礙市場成長。因此，製造商在開發和商業化創新支架方面可能面臨挑戰，這些支架既要能降低這些風險，又要兼具成本效益，並讓廣大患者能夠輕鬆獲得。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概覽
• 市場亮點

第3章市場概述

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機會
• 波特五力分析

4. 非血管支架市場（依產品類型）

• 消化道支架
• 泌尿系統支架
• 肺動脈支架
• 膽道支架
• 胰管支架

5. 非血管支架市場依材料類型

• 金屬支架
• 塑膠/聚合物支架
• 生物分解性支架
• 混合支架

6. 非血管支架市場（依應用）

• 消化系統疾病
• 泌尿系統疾病
• 肺部疾病
• 膽道疾病
• 胰臟疾病

第7章區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第8章市場動態

• 市場促進因素
• 市場限制
• 市場機會
• COVID-19 市場影響

第9章 競爭態勢

• 主要企業
• 市場佔有率分析

第10章 公司簡介

• Becton, Dickinson and Company（BD）
• Boston Scientific Corporation
• CONMED Corporation
• Cook Medical
• ELLA-CS, sro
• Glaukos Corporation
• Medtronic
• Micro-Tech（Nanjing）Co., Ltd.
• Merit Medical Systems

第11章 市場展望與機會

• 新興技術
• 未來市場趨勢
• 投資機會

第12章 附錄

• 簡稱列表
• 來源和參考文獻

Non Vascular Stents Market Valuation - 2026-2032

The prevalence of chronic diseases requiring stenting procedures, such as biliary, gastrointestinal, and urological disorders, is increasing. As populations age, the prevalence of these conditions increases, necessitating a greater need for effective treatment options such as non-vascular stenting. Technological advancements have also played an important role in the development of innovative stent designs, such as biodegradable and drug-eluting stents, which improve patient outcomes while lowering the risk of complications such as restenosis and migration driving the market growth surpassing USD 1.21 Billion in 2024 and reaching USD 1.71 Billion by 2032.

Furthermore, the growing preference for minimally invasive procedures has accelerated the use of non-vascular stents, which are associated with shorter recovery times and lower risks than traditional surgical methods. Together, these factors are driving demand for non-vascular stents, positioning the market for further growth is expected to grow at a CAGR of about 4.80% from 2026 to 2032.

Non Vascular Stents Market: Definition/ Overview

Non-vascular stents are medical devices that open or unblock ducts and passageways in non-vascular organs such as the bile ducts, ureters, esophagus, and intestines. Their primary use is to treat conditions such as obstructions, strictures, and tumors that obstruct the natural flow of these organs, providing an important solution in gastrointestinal, urological, and respiratory medicine. The future of non-vascular stents looks promising, thanks to advances in stent materials and designs like biodegradable and drug-eluting stents, which are expected to improve patient outcomes, reduce complications, and expand their use in broader clinical applications. As the prevalence of chronic diseases continues to rise, the demand for these minimally invasive treatments will grow, making non-vascular stents an increasingly vital component of modern healthcare.

Will Increasing Prevalence of Chronic Diseases Drive the Non Vascular Stents Market?

The rising incidence of chronic diseases is a major driver of the non-vascular stents market. Chronic conditions such as biliary, gastrointestinal, and urological disorders frequently necessitate stenting procedures to keep ducts and passageways open. As these diseases become more common, particularly in older populations, the demand for non-vascular stents is expected to rise. For example, the increasing prevalence of biliary diseases, such as bile duct obstruction caused by gallstones or tumours, necessitates the use of biliary stents to relieve blockages and improve patient outcomes.

In October 2024, Boston Scientific announced the introduction of a new fully covered metal stent for the treatment of benign biliary strictures, reflecting ongoing innovation aimed at improving stent performance and patient safety. Such technological advancements not only improve the efficacy of stents, but also broaden their application to a variety of chronic conditions, driving market growth.

In June 2024, the FDA approved a new drug-eluting esophageal stent, providing a novel treatment option for patients with esophageal cancer. This approval demonstrates the growing regulatory support for advanced stent technologies, which is expected to spur additional research and development in the field. As governments and healthcare organizations continue to prioritize the treatment of chronic diseases, the non-vascular stents market is expected to grow steadily in the coming years.

Will Rising Risk of Complications of Infection Hamper the Non Vascular Stents Market?

The rising risk of complications, particularly infections, is a major concern that may impede the growth of the non-vascular stents market. Infections associated with stent placement are a serious concern because they can have serious consequences for patients, such as longer hospital stays, additional surgeries, and higher healthcare costs. The fear of such complications may deter both physicians and patients from choosing stent-based treatments, limiting the market's potential growth.

Furthermore, the risk of infection can have an impact on the reputation and use of non-vascular stents. Healthcare providers may be more cautious about recommending stent procedures if infection risks are increased, particularly in vulnerable patient populations. This cautious approach may slow the adoption of new stent technologies, despite advancements in design and materials to reduce infection risks.

In addition to these direct consequences, the increased risk of complications such as infection may lead to stricter regulatory requirements for the approval of new stent products. This could increase the time and cost of bringing new stents to market, stifling market growth. As a result, manufacturers may face difficulties in developing and marketing innovative stents that can mitigate these risks while remaining cost-effective and accessible to a wide range of patients.

Category-Wise Acumens

Will Rising Demand of Gastrointestinal Stents Propel the Non Vascular Stents Market?

The increasing demand for gastrointestinal stents is expected to significantly boost the non-vascular stents market. Gastrointestinal stents are critical for managing a variety of conditions, including esophageal strictures, gastrointestinal obstructions, and tumors, all of which are becoming more common as the population ages and chronic diseases such as cancer become more prevalent. The growing demand for effective solutions in these areas is resulting in the dominance of gastrointestinal stents, driving market growth.

In March 2024, Medtronic announced the release of an advanced esophageal stent, with the goal of improving patient outcomes through increased durability. This development reflects ongoing innovation aimed at improving the efficacy and safety of gastrointestinal stents in response to rising demand caused by complex medical conditions. Such innovations not only broaden the market, but also increase the popularity of gastrointestinal stents in clinical practice.

For instance, in July 2024, the US FDA granted expedited approval for a new biodegradable stent intended for use in the GI tract. This regulatory endorsement emphasizes the commitment to improving treatment options for gastrointestinal disorders and encourages wider use of stents. As healthcare policies prioritize advanced treatment technologies, the non-vascular stents market is expected to expand further, driven by rising demand for gastrointestinal stents.

However, the urological stents segment is expected to grow at the fastest rate. This expansion is fueled by the rising prevalence of urological disorders such as kidney stones and benign prostatic hyperplasia (BPH). The rising prevalence of these conditions, combined with advances in stent technology that improve patient outcomes and reduce complications, is driving the rapid growth of the urological stents market.

Will Rising Usage of Metal Stents Drive the Non Vascular Stents Market?

The increasing use of metal stents is expected to fuel significant growth in the non-vascular stents market. Metal stents, which are known for their durability and structural integrity, are used to treat a variety of non-vascular conditions, including biliary obstructions and esophageal strictures. Their ability to provide long-term support and keep ducts and passageways open has made them a popular choice among clinicians, resulting in increased demand and market expansion.

In August 2024, the European Medicines Agency (EMA) approved a new generation of metal stents with advanced features for gastrointestinal use. This regulatory approval demonstrates the industry's commitment to improving stent technology and encouraging wider adoption. As regulatory bodies continue to support innovative solutions and address clinical needs, the non-vascular stents market is expected to benefit from increased use of metal stents, owing to their proven efficacy and technological advancements.

Biodegradable stents are the fastest growing segment. This rapid growth is driven by their innovative design, which overcomes the limitations of traditional stents by gradually dissolving in the body, lowering the risk of long-term complications and the need for additional procedures. The growing emphasis on patient safety and the demand for minimally invasive solutions are driving the adoption of biodegradable stents, making them a key market growth opportunity.

Country/Region-wise

Will Increasing Advanced Healthcare Infrastructure in North America Drive the Non Vascular Stents Market?

The expanding advanced healthcare infrastructure in North America is expected to drive significant growth in the non-vascular stents market. The region's robust healthcare system, which includes cutting-edge medical facilities, comprehensive patient care, and high levels of healthcare spending, encourages the widespread use of advanced medical technologies, such as non-vascular stents. Enhanced infrastructure enables the integration of cutting-edge stent technologies and gives patients access to sophisticated treatments that improve outcomes for a variety of non-vascular conditions.

Furthermore, industry advancements help to drive growth. In July 2024, Medtronic unveiled its new series of non-vascular stents, with research and development supported by the region's advanced healthcare infrastructure. This release emphasizes the importance of sophisticated healthcare environments in the development and distribution of medical technologies. As North America continues to dominate owing to investment and expanding healthcare capabilities, the non-vascular stents market is expected to grow, owing to increased access to and use of advanced medical devices.

Will Rising Awareness of Advanced Treatment Options in Asia-Pacific Propel the Non Vascular Stents Market?

Rising awareness of advanced treatment options in Asia-Pacific is expected to enable the region witness rapid growth in the non-vascular stents market. As the region's healthcare systems evolve and improve, more patients and providers are becoming aware of the advantages and accessibility of advanced medical devices such as non-vascular stents. This increased awareness is driving increased adoption of these devices, as more people seek cutting-edge treatments for conditions like gastrointestinal obstructions, urological issues, and pulmonary disorders.

In March 2024, the Indian Ministry of Health launched a national campaign to educate healthcare professionals and the public about advanced treatment technologies, such as non-vascular stents. This initiative is part of a larger effort to improve healthcare outcomes and give patients access to the most recent medical innovations. Such campaigns are critical for closing the knowledge gap and encouraging the use of advanced treatment options throughout the region.

In April 2024, Olympus Corporation introduced a new line of non-vascular stents designed specifically for the Asia-Pacific market, with innovative designs that address regional healthcare needs. This move reflects the growing demand for sophisticated medical solutions, which is driven by increased awareness and access to healthcare. As education and technology advance, the non-vascular stents market in Asia-Pacific is expected to expand significantly, driven by increased patient awareness and improved healthcare infrastructure.

Competitive Landscape

The competitive landscape of the non-vascular stents market is characterized by a mix of established companies and emerging players focusing on innovation and expanding their product portfolios. Companies are investing in R&D to develop stents with improved materials, flexibility, and biocompatibility to meet the specific needs of various non-vascular applications, such as biliary, esophageal, and ureteral stenting. Additionally, strategic partnerships, acquisitions, and regional expansions are common strategies as companies aim to enhance their market presence and reach. The market is also witnessing an increase in the adoption of minimally invasive procedures, further driving competition among manufacturers.

Some of the prominent players operating in the non vascular stents market include:

Becton

Dickinson and Company (BD)

Boston Scientific Corporation

CONMED Corporation

Cook Medical

ELLA-CS s.r.o.

Medtronic

Micro-Tech (Nanjing) Co. Ltd.

Merit Medical Systems

Latest Developments

In June 2024, The FDA approved their latest biliary stent, which has increased flexibility and anti-migration properties. This new product aims to increase patient comfort while reducing the need for repeat procedures.

In May 2024, Cook Medical introduced a new line of esophageal stents designed for easier placement and less tissue irritation. The stents are expected to gain popularity in treating both malignant and benign esophageal strictures.

In August 2024, Merit Medical Systems announced the acquisition of a smaller stent manufacturer, which will broaden their portfolio of gastroenterology products and increase their non-vascular stent market share.

In September 2024, Taewoong Medical has signed a distribution agreement with a major European medical device company to expand the reach of their non-vascular stents throughout Europe, with a focus on the esophageal and biliary stent markets.

Non Vascular Stents Market, By Category

• Product Type:
• Gastrointestinal Stents
• Urological Stents
• Pulmonary Stents
• Biliary Stents
• Pancreatic Stents
• Material Type:
• Metal Stents
• Plastic/Polymer Stents
• Biodegradable Stents
• Hybrid Stents
• Application:
• Gastrointestinal Disorders
• Urological Disorders
• Pulmonary Disorders
• Biliary Disorders
• Pancreatic Disorders
• Region:
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Non-Vascular Stents Market, By Product Type

• Gastrointestinal Stents
• Urological Stents
• Pulmonary Stents
• Biliary Stents
• Pancreatic Stents

5. Non-Vascular Stents Market, By Material Type

• Metal Stents
• Plastic/Polymer Stents
• Biodegradable Stents
• Hybrid Stents

6. Non-Vascular Stents Market, By Application

• Gastrointestinal Disorders
• Urological Disorders
• Pulmonary Disorders
• Biliary Disorders
• Pancreatic Disorders

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Becton, Dickinson and Company (BD)
• Boston Scientific Corporation
• CONMED Corporation
• Cook Medical
• ELLA-CS, s.r.o.
• Glaukos Corporation
• Medtronic
• Micro-Tech (Nanjing) Co., Ltd.
• Merit Medical Systems

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References